Statin use after age 80 has long been a clinical gray zone—where benefit, risk, and overall goals of care don’t always align cleanly.

New research is helping clarify that picture. A large observational study of adults aged 80 and older found statin use was associated with a lower risk of mortality, including among those in more advanced age brackets.

The findings are notable for a population that has historically been underrepresented in clinical trials. While statins are well-established in reducing cardiovascular risk in younger populations, their role in adults over 80 has remained less defined—often leading to inconsistent prescribing patterns.

What this study adds is direction.

The data suggests that cardiovascular risk continues to meaningfully impact outcomes even in later decades of life, and that statin therapy may still play a role in reducing that risk. Importantly, the association with lower mortality was observed across a broad cohort, reinforcing that benefit does not necessarily diminish solely due to age.

At the same time, the study does not suggest a one-size-fits-all approach. As with most observational data, results reflect associations rather than causation, and individual clinical context remains critical.

In senior care settings, that context matters.

Statin decisions are rarely made in isolation. They sit within a broader clinical picture that includes multiple chronic conditions, varying levels of cognitive and functional status, and differing goals of care. What the research reinforces is not a mandate to expand use—but a reminder that discontinuing or avoiding statins based on age alone may overlook potential benefit.

For providers, the takeaway is a shift in how these decisions are framed:

• Age should not be the sole determining factor
• Cardiovascular risk remains relevant in advanced age
• Decisions should reflect current condition, not historical assumptions
• Ongoing evaluation is essential as resident status changes

This is where consistency becomes important.

Without a structured approach to medication review, decisions can vary widely across providers and settings. That variability can lead to missed opportunities—either continuing medications without clear benefit or discontinuing therapies that may still contribute to stability.

Consistent, clinically informed medication review helps bring alignment to those decisions—ensuring therapies are evaluated against current risk, benefit, and goals of care.